Lantheus logo

Lantheus Share Price (NASDAQ: LNTH)

$56.84

1.18

(2.12%)

Last updated on

Check the interactive Lantheus Stock chart to analyse performance

Lantheus stock performance

as on August 28, 2025 at 1:29 am IST

  • Today's Low:$55.80
    Today's High:$56.93

    Day's Volatility :1.98%

  • 52 Weeks Low:$47.25
    52 Weeks High:$118.21

    52 Weeks Volatility :60.03%

Lantheus Stock Returns

PeriodLantheus HoldingsSector (Health Care)Index (Russel 2000)
3 Months
-24.74%
4.2%
0.0%
6 Months
-37.87%
-8.0%
0.0%
1 Year
-48.19%
-12.0%
0.0%
3 Years
-29.12%
7.7%
-6.9%

Lantheus Holdings Key Stats

Check Lantheus key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$55.66
Open
$55.8
Today's High
$56.93
Today's Low
$55.8
Market Capitalization
$3.8B
Today's Volume
$812.1K
52 Week High
$118.21
52 Week Low
$47.25
Revenue TTM
$1.5B
EBITDA
$494.0M
Earnings Per Share (EPS)
$3.76
PE Ratio
14.8
Profit Margin
17.82%
Quarterly Earnings Growth YOY
0.27%
Return On Equity TTM
24.71%

Stock Returns calculator for Lantheus Stock including INR - Dollar returns

The Lantheus stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Lantheus investment value today

Current value as on today

₹56,494

Returns

₹43,506

(-43.51%)

Returns from Lantheus Stock

₹48,191 (-48.19%)

Dollar Returns*

₹4,685 (+4.68%)

Indian investors sentiment towards Lantheus Stock

113.51%

Period: Jul 28, 2025 to Aug 27, 2025. Change in 30 Days versus previous period

Investment in Lantheus Shares from India has grown by 113.51% over the past 30 days, indicating increased transactional activity.

123%

Period: Jul 28, 2025 to Aug 27, 2025. Change in 30 Days versus previous period

Search interest for Lantheus Stock from India on INDmoney has increased by 123% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Lantheus Holdings

  • Name

    Holdings %

  • BlackRock Inc

    12.88%

  • HHG PLC

    10.21%

  • Vanguard Group Inc

    10.06%

  • Farallon Capital Management, L.L.C.

    8.86%

  • FMR Inc

    3.88%

  • State Street Corp

    3.88%

Analyst Recommendation on Lantheus Stock

Rating
Trend

Buy

    88%Buy

    11%Hold

    0%Sell

Based on 17 Wall street analysts offering stock ratings for Lantheus(by analysts ranked 0 to 5 stars)

Lantheus Share Price Target

What analysts predicted

Upside of 54.82%

Target:

$88.00

Current:

$56.84

Lantheus share price target is $88.00, a slight Upside of 54.82% compared to current price of $56.84 as per analysts' prediction.

Lantheus Stock Insights

  • Price Movement

    In the last 7 days, LNTH stock has moved down by -5.9%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 372.76M → 378.04M (in $), with an average increase of 1.4% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -11.79M → 78.75M (in $), with an average increase of 61.8% per quarter
  • LNTH vs NBIX (1 yr)

    In the last 1 year, Neurocrine Biosciences Inc. has given 10.6% return, outperforming this stock by 59.8%
  • LNTH vs HLN (3 yr)

    In the last 3 years, Haleon Plc Spon Ads has given 30.6% return, outperforming this stock by 62.3%
  • Price to Sales

    ForLNTH every $1 of sales, investors are willing to pay $2.6, whereas for Neurocrine Biosciences Inc., the investors are paying $5.5 for every $1 of sales.

Lantheus Holdings Financials

Revenue
Profit
Cash Flow
Annually
Quarterly
FY19
FY20
FY21
FY22
FY23
FY24
FY24Y/Y Change
Revenue
$1.5B
↑ 18.32%
Net Income
$312.4M
↓ 4.35%
Net Profit Margin
20.37%
↓ 4.83%

Lantheus Technicals Summary

Sell

Neutral

Buy

Lantheus is currently in a neutral trading position according to technical analysis indicators.

Lantheus Holdings Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Lantheus Holdings logo
-21.27%
-37.87%
-48.19%
-29.12%
131.15%
Haleon Plc Spon Ads logo
-1.02%
-0.82%
-2.8%
59.97%
31.04%
United Therapeutics Corporation logo
2.62%
-5.65%
-15.14%
40.39%
71.72%
Zoetis Inc. logo
2.89%
-5.82%
-15.06%
-1.58%
-2.95%
Neurocrine Biosciences Inc. logo
2.94%
17.55%
11.61%
31.15%
18.65%

About Lantheus Holdings

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Organization
Lantheus
Employees
808
CEO
Mr. Brian A. Markison
Industry
Health Technology

Key Management of Lantheus Holdings

NameTitle
Mr. Brian A. Markison
CEO & Director
Mr. Paul M. Blanchfield
President
Mr. Robert J. Marshall Jr., CFA
CFO & Treasurer
Dr. Jean-Claude Provost M.D.
Chief Science Officer
Mr. Daniel M. Niedzwiecki
Chief Administrative Officer, General Counsel & Corporate Secretary
Ms. Amanda M. Morgan
Chief Commercial Officer (Leave of Absence)
Ms. Kimberly Brown
Chief Accounting Officer
Dr. Ludger Dinkelborg Ph.D.
Head of Research & Development
Ms. Dorothy Barr
Senior Vice President of Manufacturing & Technical Operations
Ms. Lee Anne Howe
Chief Information Officer

Important FAQs about investing in LNTH Stock from India :

What is Lantheus share price today?

Lantheus share price today is $56.84 as on at the close of the market. Lantheus share today touched a day high of $56.93 and a low of $55.80.

What is the 52 week high and 52 week low for Lantheus share?

Lantheus share touched a 52 week high of $118.21 and a 52 week low of $47.25. Lantheus stock price today i.e. is closed at $56.84, lower by 51.92% versus the 52 week high.

How to invest in Lantheus Stock (LNTH) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Lantheus on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Lantheus Shares that will get you 0.0264 shares as per Lantheus share price of $56.84 per share as on August 28, 2025 at 1:29 am IST.

What is the minimum amount required to buy Lantheus Stock (LNTH) from India?

Indian investors can start investing in Lantheus (LNTH) shares with as little as ₹87.86 or $1 (as of August 28, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹878.60 in Lantheus stock (as per the Rupee-Dollar exchange rate as on August 28, 2025). Based on Lantheus share’s latest price of $56.84 as on August 28, 2025 at 1:29 am IST, you will get 0.1759 shares of Lantheus. Learn more about fractional shares .

What are the returns that Lantheus has given to Indian investors in the last 5 years?

Lantheus stock has given 131.15% share price returns and 18.89% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?